Abstract |
A new dosage formulation (ACR-CH), composed of aclarubicin (ACR) bound to fine activated carbon particles, has been developed for the treatment of lymph node metastases in breast cancer. ACR-CH is designed to (a) adsorb a great amount of aclarubicin and desorb in a free state; (b) distribute a greater amount of ACR for a longer period of time selectively to the regional lymph nodes; (c) be decreased in the systemic toxicity; and (d) enhance its therapeutic effect on lymph node metastases. In this clinical trial in 20 patients with breast cancer, ACR-CH was injected intra- and peritumorally just before operation for breast cancer, and we examined the extent of blackened nodes produced by ACR-CH. ACR-CH blackened about 70% of the axillary lymph nodes with cancer metastasis as well as the nodes without metastasis. In conclusion, ACR-CH will be useful for dissection of lymph nodes by visualizing the nodes during operation for breast cancer.
|
Authors | T Imanishi, A Hagiwara, K Sawai, T Yamaguchi, C Sakakura, M Shirasu, M Ohgaki, J Yamasaki, T Togawa, T Takahashi |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 24
Issue 12
Pg. 1796-8
(Sep 1997)
ISSN: 0385-0684 [Print] Japan |
PMID | 9382535
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Antibiotics, Antineoplastic
- Dosage Forms
- Carbon
- Aclarubicin
|
Topics |
- Aclarubicin
(administration & dosage, pharmacokinetics)
- Animals
- Antibiotics, Antineoplastic
(administration & dosage, pharmacokinetics)
- Breast Neoplasms
(pathology, surgery)
- Carbon
(pharmacokinetics)
- Dosage Forms
- Female
- Humans
- Lymph Node Excision
- Lymph Nodes
(pathology)
- Lymphatic Metastasis
(pathology)
- Rats
|